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Background: The pathogenesis of allergic airway inflammation in asthmatic patients is complex and characterized
by cellular infiltrates and activity of many cytokines and chemokines. Both the transcription factor hypoxia inducible
factor-1 (HIF-1) and chemokine CCL2 have been shown to play pivotal roles in allergic airway inflammation. The
interrelationship between these two factors is not known. We hypothesized that the expression of HIF-1 and CCL2
may be correlated and that the expression of CCL2 may be under the regulation of HIF-1. Several lines of evidence
are presented to support this hypothesis.
Methods: The effects of treating wild-type OVA (ovalbumin)-sensitized/challenged mice with ethyl-3,
4-dihydroxybenzoate (EDHB), which upregulate HIF, on CCL2 expression, were determined. Mice conditionally
knocked out for HIF-1β was examined for their ability to mount an allergic inflammatory response and CCL2
expression in the lung after intratracheal exposure to ovalbumin. The association of HIF-1α and CCL2 levels was also
measured in endobronchial biopsies and bronchial fluid of asthma patients after challenge.
Results: We show that both HIF-1α and CCL2 were upregulated during an OVA (ovalbumin)-induced allergic
response in mice. The levels of HIF-1α and CCL2 were significantly increased following treatment with a
pharmacological agent which upregulates HIF-1α, ethyl-3,4-dihydroxybenzoate (EDHB). In contrast, the expression
levels of HIF-1α and CCL2 were decreased in the lungs of mice that have been conditionally knocked out for ARNT
(HIF-1β) following sensitization with OVA when compared to levels in wild type mice. In asthma patients, the levels
of HIF-1α and CCL2 increased after challenge with the allergen.
Conclusions: These data suggest that CCL2 expression is regulated, in part, by HIF-1 in the lung. These findings
also demonstrate that both CCL2 and HIF-1 are implicated in the pathogenesis of allergic airway inflammation.
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Asthma is a global health concern with increasing
prevalence of morbidity and mortality worldwide [1].
Asthma is a chronic inflammatory disease resulting in
the overproduction of mucus, airflow obstruction, and
airway hyperresponsiveness. The pathogenesis of
asthma includes an exaggerated immune response to
an allergen. This, in turn, activates CD4 T helper-2
(Th2) lymphocytes and the release of specific cytokines
(including IL-4, IL-5, and IL-13) and chemokines (in-
cluding CCL2, CCL3, CCL4, CCL5 CCL11 and
CCL24) [2,3]. These cytokines and chemokines induce
increased airway inflammation, including eosinophil
recruitment [4].
Monocyte chemotactic protein 1 (MCP-1/CCL2) is a
member of the CC family of chemokines [5], a potent
chemoattractant for macrophages [6], and also attracts
CD4+ and CD8+ T-lymphocytes [7]. Increasing evidence
suggests that CCL2 and its haematopoietic cell receptor
CC chemokine receptor 2 (CCR2) are involved in in-
flammatory disorders of the lungs [7]. CCL2 may have a
significant role in the pathogenesis of asthma because of
its ability to recruit eosinophils and monocytes, activate
basophils and mast cells and induce the release of leuko-
triene C4 into the airway, all of which contribute to air-
way hyperresponsiveness [8]. CCL2 can also direct
undifferentiated T-lymphocytes towards interleukin-4
(IL-4)-producing Th2 cells [9,10]. Overexpression of
CCL2 has been observed in the bronchial epithelium of
asthmatic patients [11]. CCL2 is also significantly upre-
gulated after challenge in asthmatic patients [12].
Sensitization and challenge with cockroach Ag in mice,
in which CCL2 activity was blocked with a specific anti-
murine MCP-1 antibody, showed a decrease in several
allergic inflammatory manifestations such as histamine
and LTC4 levels, and attenuated airway hyperreactivity
in sensitized mice [13]. Additionally, CCR2−/− mice
have an attenuated airway hyperreactive response during
allergen challenge or after direct instillation of CCL2,
implicating a CCR2-mediated mechanism. Furthermore
the neutralization of CCL2 during the allergic airway re-
sponse decreased histamine in the BAL. [8]. These
results support an important role for CCL2 in the asth-
matic response.
CCL2 is known to be regulated by oxidative stress,
cytokines and growth factors. In addition, CCL2 is also
associated with hypoxic regulation. CCL2 was induced
by both hypoxia and CoCl2 in human astrocytes and
the promoter of CCL2 contains hypoxia response ele-
ments (HREs) which can bind hypoxia inducible factor-
1 (HIF-1) [14].
The transcriptional response to hypoxia is primarily
mediated by the hypoxia inducible factor (HIF) family of
transcription factors. HIFs are heterodimeric proteinscontaining one α subunit and one β subunit. HIF-1α and
HIF-2α (collectively called the HIF-α subunits) are both
expressed widely, as is HIF-1β (also called the Aryl
Hydrocarbon Receptor Nuclear Translocator [ARNT]).
All of the HIF subunits belong to the basic helix-loop-
helix (bHLH)/Per-ARNT-Sim (PAS) domain family of
transcription factors. The β subunit is constitutively
expressed, and the regulation of HIFs occurs mainly via
effects on the α subunits. Under normoxic conditions,
the HIF-α subunits are hydroxylated on key proline resi-
dues, which allows for their recognition by the von
Hippel-Lindau (pVHL) tumor suppressor protein, the
substrate recognition component of an E3 ubiquitin lig-
ase complex that targets HIF-α for proteasomal degrad-
ation. Hydroxylation of both prolines is catalyzed by a
family of three prolyl hydroxylases. Another level of
HIF-1α regulation occurs through the hydroxylation of
an asparagine residue by Factor Inhibiting Hypoxia In-
ducible Factor-1α (FIH) which prevents HIF-1α from
interacting with the coactivator p300 under normoxic
conditions [15,16]. During hypoxia, prolyl hydroxylases
are inactive allowing HIF-1α to dimerize and form a
complex with its partner ARNT and then binds HREs in
the promoter regions of target genes, upregulating their
transcription [17].
HIF-1α can be upregulated during inflammation as a
consequence of the hypoxic microenvironment or via a
hypoxia-independent mechanism [18]. HIF-1α can also
regulate the expression of several relevant factors, in-
cluding pro-inflammatory cytokines, chemokines, and
adhesion molecules. Enhanced levels of HIF-1α, 2α and
VEGF have been identified in lung tissues and bronchial
epithelial cells of asthmatic patients as well as in the
bronchial lavage of asthmatic patients, where they were
associated with elevated levels of eosinophil counts as
compared to persons without asthma [19]. Moreover, a
direct correlation was found between the levels of HIF-
1α, 2α and VEGF [19].
We recently reported that HIF-1α is increased after
allergic challenge in asthma and rhinitis patients
[20,21]. However, the relationship between HIF-1 and
CCL2 in allergic airway inflammation has not yet been
described. In this study we found a direct association
between HIF-1α and CCL2 expression in allergic airway
inflammation in an animal model. CCL2 was upregu-
lated in vivo after treatment with a HIF-1α inducer. In
contrast, CCL2 was downregulated in mice deficient in
ARNT, an obligatory subunit necessary for HIF-1 activ-
ity. In addition, we also found a direct correlation be-
tween upregulated levels of CCL2 and HIF-1 after
challenge in samples from asthmatic patients. These
findings demonstrate for the first time, a role for HIF-
1α in the regulation of CCL2 expression in airway in-
flammatory disease.
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Breeding and genotyping of mice
The original ArntF allele contained a neo cassette, which
was excised as described previously [22]. The ArntF/F
mice, which were of a mixed C57BL/6, 129/Sv and FVB/
N genetic background, were back crossed to homozygous
Mx1-Cre +mice in a C57BL/6 genetic background (Jack-
son Laboratory, Bar Harbor, Maine). Progeny from this
cross were then backcrossed at least ten successive times
to generate a mouse strain in a 100% C57BL/6 back-
ground. Genotyping of the ArntF and ArntΔ alleles was
performed by PCR as described previously [23]. The
Mx1-Cre transgene was genotyped with PCR primers
directed at the Cre gene as described previously [23].
Mx1-Cre+/- heterozygotes could not be distinguished
from Mx1-Cre+/+ homozygotes by this procedure, and
these genotypes are collectively referred to as Mx1-Cre+.
KO mice were obtained and maintained in the facilities of
the University of California, Los Angeles (UCLA) (USA).
Balb/c male mice between 6 to 8 weeks old were
obtained and maintained in the facilities of the Instituto
Nacional de Ciencias Medicas y de la Nutrición “Salvador
Zubirán” (INCMN) (Mexico City). Mice were maintained
in a pathogen-free environment, in a temperature-
controlled room with 12-h dark/light cycles, and allowed
food and water ad libitum. All experiments were per-
formed in accordance with UCLA and INCMN animal
regulations.
Treatment of mice
Induction of the Cre protein and,thus, deletion of the
Arnt allele in Mx1-Cre:ArntF/F mice was induced by
intraperitoneal (i.p) injection with 500 μg of
polyinosinic-polycitidylic acid (pIpC, Sigma, St.Louis,
MO) in PBS on three consecutive times two days apart.
Sensitization was elicited by two i.p. treatments, five
days apart, with 100 μg of chicken egg ovalbumin (OVA,
grade V, Sigma, St. Louis, MO) emulsified in 1 mg of
aluminum hydroxide (Pierce Chemical, USA) in a total
volume of 100 μL. Mice were challenged via intratra-
cheal (i.t.) administration of 0.75% OVA on two or three
occasions as indicated. Control mice received vehicle
solvent only.
Where indicated, mice were i.p. injected with 100 mg/kg
of ethyl 3,4, dihydroxy benzoate (EDHB) (Sigma, St.Louis,
MO) in 10% DMSO. In all cases treatment with the 10%
DMSO vehicle was used as negative control. Mice were
euthanized by inhalation of isofluorane. All experiments
were performed in accordance with UCLA and INCMN
regulations.
Lung histology and morphometric analysis
After the mice were euthanized by exsanguination, the
lungs were filled intratracheally with a fixative (absoluteethanol). The lungs were then removed and fixed with
ethanol, dehydrated and embedded in paraffin. For
histological examination, 4-μm sections of fixed embed-
ded tissues were cut on a Seea Meins model rotary
microtome (Germany), placed on glass slides, and depar-
affinized. The slides were stained sequentially with
hematoxylin and eosin (H&E) to assess inflammatory
cell infiltration. The area (μm2) of inflammation was cal-
culated from venules with diameters of 100-200 μm and
from bronchioli 150-300 μm in diameter. Four blood
vessels or bronchioli from each of four to six lung sec-
tions were analyzed for each experimental group, and
results are expressed as the average and standard devia-
tions of the infiltrated area. Mucus production was
assessed in lung sections stained with periodic acid
Schiff (PAS), focusing on bronchioli of 150-300 μm in
diameter. The PAS-positive material was measured in
200 μm squares (40,000 μm2). Five bronchioli from four
to six lung sections were analyzed for each experimental
group, and the results are expressed as the average and
standard deviation of PAS-positive area (μm). Slides
were analyzed under an Olympus BX-40 microscope.
Quantification analysis was performed using Image Pro-
plus 6.2 software (Media Cybernetics, Bethesda, MD).
Immunohistochemistry
Deparaffinized 4-μm sections were used for immunohis-
tochemical analysis of HIF-1α and CCL2. Briefly, antigen
retrieval was performed by immersing the slides in
0.01 M sodium citrate, pH 6.0, for twentyfive minutes in
boiling water. Endogenous peroxidase activity was inhib-
ited by immersing the slides in 3% H2O2 -methanol for
20 min, and background nonspecific binding was
reduced by incubating with 1% normal swine serum
(NSS) in PBS for 60 min. The slides were incubated
overnight at room temperature with antibodies against
HIF-1α (1:250 dilution, Santa Cruz Biotechnology, Santa
Cruz, CA), and CCL2 (1:500 dilution, Santa Cruz). Fi-
nally, the slides were washed five times in PBS 1X, pH
7.4, for eight minutes. In order to reduce variability, all
samples from each group were processed at the same
time in a single experiment using a single batch of anti-
body diluted in PBS with normal swine serum. After
washing, the tissues were incubated with a biotinylated
secondary antibody anti-rabbit IgG (1:500) (Santa Cruz)
for HIF-1α or donkey anti-goat IgG biotin conjugate
(1:500 Santa Cruz) for CCL2 for 30 minutes at room
temperature followed by incubation with a streptavidin-
HRP for 30 minutes at room temperature, and revealed
with 3,3′-diaminobenzidine tetra-hydrochloride (DAKO,
Carpinteria, CA, USA). The reaction was arrested with
water, and the slides were counterstained with
hematoxylin. Thereafter, the tissues were washed in dis-
tilled water for five minutes, dehydrated sequentially in
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and then mounted with Cytoseal-60 (Fisher Scientific,
Pittsburgh, PA). Finally, the slides were analyzed under
light microscopy (Olympus BX-40).
Double-immunofluorescence
HIF-1α and CCL2 colocalization in cells from BAL fluid
from asthmatic patients was confirmed using immuno-
fluorescence. Cells from BAL fluid from asthmatic
patients post challenge were fixed with 4% paraformal-
dehyde with 0.2% Triton X-100. After blocking (5% goat
serum, 3% BSA, and 0.2% Triton X-100 in PBS), the cells
were incubated with anti-HIF-1α antibody for 1 h at 4°
C. After incubation, the cells were treated with an FITC-
conjugated anti-rabbit antibody (Jackson Immunore-
search, PA). For CCL2 detection, the cells were treated
with murine anti-CCL2 antibody and developed with
phycoeritryn-conjugated anti-goat antibody (Jackson
Immunoresearch, PA). After double-staining, the cells
were mounted using Gel/Mount (Biomeda Corp.). Im-
munofluorescence was examined and photographed with
a Olympus B24 microscope equipped with epifluores-
cence illumination.
Bronchoalveolar lavage (BAL) of mice
After the mice were euthanized by exsanguination, the
tracheas were exposed and intubated with a polyethylene
catheter. The BAL fluid was collected by washing with
two separate aliquots of 1 ml of sterile saline (SS) con-
taining 2% of fetal bovine serum (FBS) through the tra-
chea. The cells from both washes were harvested by
centrifugation (500 × g for 10 min at 4 °C). CCL2 in BAL
supernatant fluid was determined by ELISA.
ELISA
The quantification of serum levels of CCL2 was per-
formed using an ELISA protocol. Briefly, micro ELISA
plates were coated with monoclonal CCL2 antibody
(R&D systems, Minneapolis, MN) diluted 1:500, for 2
hours. The plates were washed three times, and then
blocked with chicken egg OVA (Sigma, St.Louis, MO).
The plates were then washed three times and secondary
antibody (R&D systems, Minneapolis, MN), diluted at
1:1000 was added. After four hours, AP-strepavidin
(Zymed, San Francisco, CA) was added at a dilution of
1:1000, and the plate was incubated for 1 hour. BluePhos
(KPL, Gaithersburg, MD) was used to develop the reac-
tion and the plate was read at 650 nm within 2 hours.
Human subjects
Nine mild to moderate asthmatic subjects who were ster-
oid naïve and cat allergic were studied (6 female/3 male;
age 26± 7.0 years; mean FEV1 [forced expiratory volume
in 1 second] of 96± 8%). Subjects underwent a baselinefiberoptic bronchoscopy (FOB) in which endobronchial bi-
opsies and bronchoalveolar lavage (BAL) were obtained.
Three days later, subjects underwent a naturalistic cat
room challenge (previously described) [24,25] until their
FEV1 dropped by 20% or for an hour, whichever occurred
first (Fel d 1 cat antigen protein concentration was
17.2± 5.8 ng Fel d 1/cu meter air). Three days later, sub-
jects again underwent FOB to obtain biopsies and BAL.
Two endobronchial biopsies from a randomly selected
side were obtained from subsegmental or segmental cari-
nii and placed in cassettes in 4% paraformaldehyde, trans-
ferred to 70% ETOH and then paraffin embedded and
stored until immunohistochemistry (IHC) was performed.
Bronchoalveolar lavage was performed with normal saline
in (sub) segments of the right middle lobe or lingula in a
randomized manner. 40 and 50 ml were instilled and with-
drawn by syringe aspiration, filtered through a 100 μ filter,
and placed on ice. The BAL was spun down at 3000 RPM
for 10 minutes, the cell pellet was resuspended in fetal bo-
vine serum (FBS), and cytospins were made (100,000 cells
per slide) and stained for cell count and differential (H&E)
or fixed in 4% paraformaldehyde and stored in PBS for
IHC.
All subjects signed an informed consent and study ac-
tivities were approved by the Human Subject Protection
Committee of the University of California, Los Angeles.
Cytoimmunostaining
Cytospins from BAL were fixed in 10% formalin and
stained for HIF-1α and CCL2 as described above in the
immunohistochemistry protocol.
Statistical analysis
Data are expressed as mean ± S.E.M. Statistical compari-
sons were performed using one-way analysis of variance
followed by ANOVA. Significant differences between
groups were determined using the unpaired Student’s t-test.
Statistical significance was set at p< 0.05. For the correl-
ation between HIF-1α and CCL2 expression in the human
samples, we used Pearson’s correlation analysis.
Results
Induction of HIF-1α results in CCL2 overexpression
We investigated whether upregulation of HIF-1α would
affect CCL2 expression. We used EDHB, which inhibits
prolyl hydroxylases competitively with regard to two of
their cosubstrates, oxoglutarate and ascorbate [26]. Balb/c
mice were sensitized with OVA, i.p., on days 0 and 5. Next,
EDHB was injected, i.p. on three occasions, one day before
each ntratracheal challenge with OVA, and the mice were
sacrificed four days after the last OVA treatment
(Figure 1A). The inflammatory response was measured in
lung tissue using H&E and PAS staining (Figure 1B). OVA
treatment led to an increase in perivascular (Figure 1Bc)
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with OVA and EDHB (Figure 1Bd and 1Bh) led to a mark-
edly enhanced inflammatory response compared with
treatment with OVA alone. EDHB elicited a modest in-
flammatory response by itself (Figure 1Bb and 1Bf). In
addition, PAS staining showed an increase in mucusA B
C D
Figure 1 Increased HIF expression enhances allergic airway inflamma
Experimental Protocol. Balb/c mice were sensitized with OVA in alum, i.p., o
and 32. Mice were treated with 100 mg/kg EDHB, i.p., 24 prior to each cha
B. Representative H&E stained sections of lung tissues showing blood vesse
(OVA) (c and g) and OVA sensitized/challenged mice treated with EDHB (O
and SS/EDHB (b and f) are presented in the upper panel. Representative PA
OVA/EDHB (l), SS (i) or SS/EDHB (j) are also presented in the top panel. Qua
five mice from each experimental group is presented in the bottom panel.
veins 100–200 μm in diameter and in bronchioles 150–300 μm in diamete
described in “Materials and Methods.” Results are expressed as means and
EDHB; (grey) OVA; (solid) OVA/EDHB. *p = 0.01 OVA vs. OVA/EDHB mice. C.
expression in the lung tissue of representative mice treated with OVA (c an
shown in the upper panel. Quantification of HIF-1α and CCL2 immunostain
experimental group is presented in the lower panel. Five lung sections wer
mice. D. Quantification of CCL2 in BALF of mice treated with saline (empty
*p = 0.002 OVA vs. OVA/EDHB mice.production in mice treated with OVA (Figure 1Bk) as
compared to saline treated mice (Figure 1Bi). Enhanced
mucus production was observed after treatment with the
combination of OVA and EDHB (Figure 1Bl) as compared
to OVA alone. EDHB treatment alone did not induce
mucus production (Figure 1Bj). Quantitation of thetion and CCL2 levels in OVA sensitized/challenged mice. A.
n days 0 and 5, followed by a challenge with OVA, i.t., on days 12, 22
llenge. Mice were sacrificed 4 days after the last challenge, on day 36.
ls (a-d) or bronchioles (e-h) obtained from OVA-sensitized/challenged
VA/EDHB) (d and h) or control mice treated with saline (SS) (a and e)
S stained sections of lung tissue from OVA-sensitized mice (k) and
ntification of the inflammatory response and mucus production for
The degree of inflammatory infiltration in venules and middle size
r from five mice from each experimental group was determined as
standard deviations of infiltrate area. (empty) saline control; (light grey)
Immunohistochemical staining of HIF-1α (a-d) and CCL2 (e-h)
d g), OVA/EDHB (d and h), SS (a and e) and SS/EDHB (b and f) is
ing in the vessels and bronchioles of five mice from each
e analyzed for each experimental group. *p = 0.001 OVA vs. OVA/EDHB
bar), SS/EDHB (light grey), OVA (grey) and OVA/EDHB (solid bar).
Baay-Guzman et al. Respiratory Research 2012, 13:60 Page 6 of 11
http://respiratory-research.com/content/13/1/60inflammatory response (Figure 1B bottom panel) shows
that the observed differences were statistically significant.
Immunohistochemical analysis (Figure 1C) demon-
strated that OVA and EDHB enhanced the expression of
HIF-1α (Figure 1Cd) and CCL2 (Figure 1Ch) above the
levels elicited by OVA alone (Figure 1Cc and g). VEGF
expression was also significantly upregulated (data not
shown) [21]. Lungs of saline-treated mice did not show
significant expression of either HIF-1α or CCL2
(Figure 1Ca and e). EDHB alone slightly upregulated
HIF-1α and CCL2 expression (Figure 1Cb and 1Cf).
Quantification of the expression of HIF-1α and CCL2
revealed that the enhanced expression of both proteins
in response to OVA and OVA and EDHB treatment was
statistically significant (Figure 1C, bottom panel). Fur-
thermore, using flow cytometry, we determined that
macrophages were the principal cells expressing HIF-1α
and CCL2, while B and T cells expressed lower levels of
these proteins; dendritic cells expressed modest amounts
of the proteins. In addition we found a higher amount of
HIF-1 and CCL2 doubly-stained positive cells in OVA-
sensitized mice as compared with control mice (data not
shown).
Thus, during airway inflammation, CCL2 was upregu-
lated by EDHB, an agent which upregulates HIF and at
least one of its target genes, VEGF (data not shown)
[21]. In addition, we analyzed the expression of CCL2 in
the lavage of treated mice. We found a significant in-
crease in the expression of CCL2 in the lavage fluid of
the OVA and EDHB treated mice as compared to mice
treated with OVA alone (Figure 1D).
CCL2 expression is reduced in mice deficient in ARNT
Mice that are homozygous for an Arnt null allele (i.e.
Arnt knockout mice) die in utero [27,28]. We, there-
fore, used conditionally knocked out mice in which de-
letion of the Arnt gene can be deleted in adulthood
[21]. Briefly, the ARNT allele in the ArntF/F:Mx1-Cre
mice can be deleted with treatment with polyinosinic-
polycytidylic acid (pIpC), which activates transcription
of the Cre gene. The Cre recombinase catalyzes deletion
of the genomic segment between two loxP sites. Thus,
in ArntF/F:Mx1-Cre+ mice i.p. injected with pIpC, in-
activation of the Arnt gene occurs in most tissues of
the body and at about 80% efficiency in the lung [22].
In order to test our hypothesis that HIF-1 plays a role
in CCL2 expression during airway inflammation, we
examined the expression of CCL2 in mice sensitized
and challenged with OVA and deficient for the ARNT
allele.
Eight ArntF/F:Mx1-Cre mice per group were used in
these experiments. The mice received pIpC to delete the
Arnt gene. Mice were subjected to a previously described
allergenic protocol [20], involving two intraperitonealtreatments with the allergen OVA, and the adjuvant,
alum, followed by three intratracheal administrations of
OVA (Figure 2A). Routine H&E stained lung sections
were used to evaluate the degree of inflammatory cell in-
filtration (Figure 2B). OVA treatment in the Cre- mice
elicited a marked perivascular (Figure 2Bb) and peri-
bronchiolar (Figure 2Be) inflammatory infiltration, com-
prised mostly of mononuclear cells. The Cre+ mice
treated with OVA exhibited a marked reduction in the
degree of perivascular (Figure 2Bc) and peribronchiolar
(Figure 2Bf) inflammatory cell infiltration, as compared
to the similarly treated Cre- mice (Figure 2Bb and e). Sa-
line treated mice did not show any significant inflamma-
tory response (Figure 2Ba and d). The decrease in
infiltration in the Cre+ mouse lungs was statistically sig-
nificant (Figure 2B, bottom panel).
We also analyzed the expression of HIF-1α and CCL2
in the lungs of these mice. Representative lung sections
from each experimental group and quantitative analysis
of the staining in all the mice are presented in
Figure 2C. The expression of HIF-1α and CCL2 was
drastically reduced in the Cre+/OVA treated mice
(Figure 2Cc and f), as compared to the Cre-/OVA mice
(Figure 2Cb and e). OVA treatment of the Cre- mice
(Figure 2Cb and e) increased HIF-1α levels in the nu-
cleus and CCL2 levels in the cytoplasm of inflammatory
and bronchiolar epithelial cells as compared to untreated
mice (Figure 2Ca and d). Reduction of HIF-1α and
CCL2 in both vessels and bronchioles in Cre+/OVA mice
as compared to Cre-/OVA mice was statistically signifi-
cant (Figure 2C bottom panel).
CCL2 expression correlates with increased HIF-1α
expression in asthmatic patients after allergen challenge
We also evaluated CCL2 expression in human samples
(n = 9) in order to validate our findings in mice. The
subjects general clinical characteristics are described in
Table 1. We examined HIF-1α and CCL2 expression in
bronchial lavage fluid (Figure 3A) and lung tissue
(Figure 3B) derived from asthmatic patients before and
after allergen challenge. Figure 3A shows representative
photomicrographs of HIF-1α (Figure 3Aa and b) and
CCL2 (Figure 3Ac and d) immunostained cells obtained
from lavage in asthmatic patients before (Figure 3Aa and
c) and after (Figure 3Ab and d) exposure to antigen
challenge. HIF-1α and CCL2 expression was significantly
increased in cells from lavage after allergen challenge
(Figure 3A, right panel). In order to demonstrate the
coexpression of HIF-1α and CCL2 in cells from lavage,
we performed double-immunostaining (Figure 3B). Our
results demonstrate that HIF-1α (3Ba) and CCL2 (3Bb)
were colocalized in the same cells (Figure 3Bc).
In Figure 3C we show HIF-1α (Figure 3Ca and b) and
CCL2 (Figure 3Cc and d) immunostaining of lung tissue
A B
C
Figure 2 OVA sensitized/challenged mice conditionally knocked out for Arnt have a reduced allergic response in the lung and
decreased expression of CCL2. A. Experimental protocol. Mice were treated with pIpC three times, three days apart, to delete the Arnt allele.
In order to induce allergic airway inflammation, mice were sensitized with OVA in alum, i.p., on days 15 and 20, followed by a challenge with
OVA, i.t., on day 28. Mice were sacrificed on day 32, 4 days after the challenge. B. Histological analyses of lung tissue. Representative sections of
lung tissues were obtained from OVA-sensitized/challenged mice (b,c,e and f) and control mice treated with sterile saline (SS) (a and d), of
genotype ArntF/F:Mx-1-Cre– (b and e) or ArntF/F:Mx1-Cre+ (c and f). The lung tissues (a-c, blood vessels; and d-f bronchioles) were stained with H&E
and examined by light microscopy (upper panel). Quantification of the inflammatory response is shown in the lower panel. The degree of
inflammatory infiltration in venules and middle size veins 100–200 μm in diameter, and in bronchioles 150–300 μm in diameter from five mice
from each experimental group was determined as described in “Materials and Methods.” Results are expressed as averages and standard
deviations of infiltrated area. (empty bars) perivascular infiltrate; (solid bars) peribronchiolar infiltrate. *p = 0.01, **p = 0.001 Cre- OVA vs. Cre +mice.
C. Immunohistochemical staining of HIF-1α (a-c) and CCL2 (d-f) in lung tissue of representative ArntF/F:Mx1-Cre- (b and e) or ArntF/F:Mx1-Cre+
(c and f) in OVA (b,c,e and f) and saline (a and d) mice treated as described in B (upper panel). Quantification of HIF-1α and CCL2 (lower panel)
was performed as described in Figure 2B. *p< 0.05 Cre- OVA vs. Cre +mice.
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after (Figure 3Cb and d) exposure to challenge. Expres-
sion of HIF-1α was predominantly nuclear, although
some cytoplasmic staining was observed. Expression of
CCL2 was predominantly cytoplasmic or in the mem-
brane. The right panel of Figure 3C shows quantification
of the density of the expression of HIF-1α and CCL2 in
the lung tissue. Expression of HIF-1α and CCL2 was sig-
nificantly higher after challenge. Furthermore, there was
a direct correlation between HIF-1α and CCL2 expres-
sion after challenge, as measured by inmunostaining
(Figure 3D), (*p< 0.05, *r = 0.7930).These findings therefore build on our animal studies
and suggest that HIF-1 plays an important role in the
regulation of CCL2 during allergic disease in the human.
Discussion
Previous observations have implicated HIF-1 in the devel-
opment of asthma [21]. Hypoxia is a potent stimulus for
inflammation and remodeling, and HIF-1 can activate
transcription of several inflammatory cytokines, chemo-
kines and growth factors, including VEGF, as well as
matrix remodeling proteins, such as procollagen and
matrix metalloproteinases [29]. N-acetylcysteine amide
Table 1 Clinical features of patients with asthma
Asthmatic subjects
Subjects n 9
Age years 26 (18-43)
Sex M:F 3:6
FEV1% predicted 94.67 (76-112)
FEV1 (L) 3.9 (2.9-5.0)
FEV1 at 0 min (L) [CRC] 3.7 (2.6-4.9)
FEV1 Lowest (L) [CRC] 3.39 (2.5-4.3)
% FEV1 decline [CRC] 8.72 (-8.3-32.1)
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attenuated airway inflammation as well as hyperrespon-
siveness by regulating HIF-1α and NF-κB and reducingA
C
Figure 3 HIF-1α and CCL2 are both increased in BALF and lung tissue af
photomicrographs of HIF-1α (a and b) and CCL2 (c and d) immunostaining ob
before (a and c) and after (b and d) challenge. In the right panel, we quantified
a significant increase in the expression of both genes. Student t-test *p< 0.05
HIF-1α and CCL2 in BAL cells from asthmatic patients was performed using do
antibody and then with FITC-conjugated anti-rabbit antibody (a). For CCL2 det
treated with a secondary antibody with red fluorescence (b). The merging of f
co-expression of HIF-1α and CCL2 (c). C. Representative photomicrographs of H
(b and d) challenge, observed at magnification of 40X in lung tissue (left panel
in the lung tissue. In the right panel, we quantified the density of the expressio
performed from data collected from 9 patients. Student t-test *p< 0.05 Pre vs.
between HIF-1α and CCL2 positively immunostained cells after challenge. Pearreactive oxygen species (ROS) levels [30]. Inhibition of
PPAR decreased HIF-1 and NF-κB and induced attenu-
ation of the airway inflammatory response [31]. VEGF and
HIF-1α and HIF-2α were expressed at higher levels in
asthmatic patients as compared to healthy controls [19].
Most recently, Guo et al. found a significant reduction in
the number of eosinophils in BAL fluid after sensitization/
challenge with OVA in mice heterozygous for a HIF-1α
null allele as compared to wild-type mice [32]. However, a
clear mechanism of how HIF-1 is involved in perpetuating
the inflammatory response is not clear because HIF-1 reg-
ulates several chemokines and cytokines. Previous studies
have demonstrated that HIF-1α regulates CCL2 at the
transcriptional level [14]. We provide evidence for this no-
tion in the present study in that at least one mechanism
for HIF-1-mediated inflammation in the lung during anB
D
ter challenge in asthmatic patients. A. Representative
served at magnification of 100X in epithelial cells from bronchial lavage
HIF-1α and CCL2 positive cells, before and after the challenge and found
pre vs. post challenge HIF-1α and CCL2 expression. B. The colocalization of
uble-immunofluorescence. The cells were incubated with anti-HIF-1α
ection, the cells were treated with goat anti-CCL2 antibody and then
luorescence resulted in significant yellow fluorescence that indicated
IF-1α (a and b) and CCL2 expression (c and d) before (a and c) and after
). Both HIF-1α and CCL2 expression was enhanced after allergen challenge
n of HIF-1α and CCL2 before and after challenge. This analysis was
post challenge HIF-1α and CCL2 expression. D. Correlation analysis
son’s analysis (p=0.001, r = 0.878) post challenge HIF-1α vs. CCL2.
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inflammatory chemokine CCL2, mainly by macrophages,
which in turn, can recruit cells such as eosinophils and
lymphocytes to areas of inflammation.
In a previous study conducted by our group, EDHB, a
known inducer of HIF-1α both in vivo and in vitro [33],
resulted in increased levels of HIF-1α and the target
gene VEGF in the airway epithelium of mice [21]. EDHB
also enhanced the allergenic response to OVA, including
airway inflammation, goblet cell hyperplasia, and
increased mucus production, indicating that HIF-1 is
involved in generating the allergic inflammatory re-
sponse. In order to investigate whether one of the
mechanisms of HIF-1-mediated lung inflammation is via
upregulation of the pro-inflammatory chemokine CCL2,
we analyzed the effect of EDHB on airway inflammation
in combination with OVA. Mice treated with EDHB and
OVA had significantly higher expression of CCL2 than
mice treated with OVA alone and these levels correlated
with the expression of HIF-1α and the inflammatory re-
sponse (Figure 1C). EDHB alone was sufficient to induce
an inflammatory response in our model as previously
observed [21] as well as CCL2 expression. To our know-
ledge, this is the first time that a compound known to
induce HIF-1 activation has been shown to induce the
expression of CCL2 in the absence of a specific aller-
genic stimulus.
In order to validate our hypothesis that HIF-1α regulates
CCL2 during allergic airway inflammation, we utilized
mice conditionally knocked out for ARNT, which is an ob-
ligatory subunit of HIF-1 [34]. Arnt2 is not expressed in
mouse (or human) lung [22] and, therefore, its potential
effects can be excluded from our study. It should be noted
that both HIF-1α and HIF-2α are expressed in the mouse
lung [21], particularly in the bronchiolar epithelium and
lung vascular endothelium. Therefore, both α subunits are
likely to contribute towards airway inflammation. There
appears to be some redundancy between HIF-1α and
HIF-2α, since they exhibit different (although overlapping)
spectra of target genes [35]. Deleting each α subunit indi-
vidually is likely to provide limited insight into the role of
HIF-1 in the development of allergic airway inflammation.
Furthermore, interpretation of data from these mice could
be further confounded by the compensatory upregulation
of one α subunit that can occur when the other is
decreased or ablated [36–39]. Hence, our ARNT condi-
tional knock out mice are well suited for this study com-
pared to individually knocked out HIF-1α or HIF-2α
mice. It should be noted that although ARNT is also an
obligatory subunit for the Aryl hydrocarbon receptor
(AhR), C57BL/6 Ahr-null mice do not exhibit a reduced
allergic lung inflammatory response after an OVA chal-
lenge protocol very similar to the one we performed here
[40].Using our conditionally knocked out mice, we
observed a significant decrease in HIF-1α expression
and more importantly a decrease in CCL2 expression;
this observation was associated with a decreased inflam-
matory response (Figure 2C). This finding clearly
demonstrates that CCL2 is under the regulation of HIF-
α and that it is implicated in the allergic inflammatory
response. Our findings provide evidence for the import-
ant involvement of HIF-1α in the regulation of CCL2 ex-
pression in allergic inflammatory disease. Altogether, the
present study suggests that this is also likely to be the
case in humans, with possible significant clinical
implications.
We observed significant upregulation of HIF-1α and
CCL2 in epithelial cells from bronchial lavage and lung
tissue of asthmatic patients after exposure to allergen.
Although one previous study correlated HIF-1α and 2α
overexpresion in bronchial lavage and lung tissue from
asthmatic patients as compared to healthy controls, the
levels of protein were only measured in pre-challenge
conditions [19]. A recent study by our group demon-
strates a significant increase of HIF-1 and its target gene
VEGF after allergen challenge [21]. However, to our
knowledge this is the first time that a direct correlation
between HIF-1α and CCL2 expression has been shown
in asthmatic patients after cat allergen challenge.
In the current study, we provide compelling evidence
for a direct association between the expression of HIF-1
and CCL2 during allergic lung inflammation in the
mouse using a combination of pharmacological and gen-
etic approaches. We also provide evidence for this asso-
ciation in asthmatic patients. Our animal studies and
supporting human data indicate an important role for
the HIF-1α-mediated allergic inflammatory response
possibly via regulation of the pro-inflammatory chemo-
kine CCL2. Further studies will have to address the dir-
ect regulation of CCL2 by HIF-1 during allergic airway
inflammation. Furthermore, although CCL2 may not be
considered an ideal pharmacotherapeutic target for the
treatment of asthma, our results indicate that HIF-1α
may be used as a specific target.
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